Statins and Blockers of the Renin-Angiotensin System
- 1 October 1999
- journal article
- lecture
- Published by Wolters Kluwer Health in Hypertension
- Vol. 34 (4) , 987-996
- https://doi.org/10.1161/01.hyp.34.4.987
Abstract
In addition to their primary mode of action, statins and blockers of the renin-angiotensin system possess common additional properties that are under active investigation. The inhibition of cellular proliferation, the restoration of endothelial activity, the inhibition of platelet reactivity, and an antioxidant potential are only a few examples of shared effects that target the arterial wall. These and other properties may eventually become exploited for the improved treatment of cardiovascular diseases and of other diseases apparently unrelated to the cardiovascular field, including inflammation and cancer. This review analyzes the current knowledge on the pleiotropic properties of these classes of drugs. Direct comparison indicates that study of the associations among these drugs may eventually disclose additive or synergistic effects that, perhaps even at lower dosages, may provide improved vascular protection and a strong alliance against several atherogenic mechanisms.Keywords
This publication has 59 references indexed in Scilit:
- Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yetThe American Journal of Cardiology, 1999
- Low-density lipoproteins and risk for coronary artery diseaseThe American Journal of Cardiology, 1998
- The antihypertensive profile of the angiotensin AT1 receptor antagonist, GR138950, and the influence of potential homeostatic compensatory mechanisms in renal hypertensive ratsBritish Journal of Pharmacology, 1998
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Sodium-lithium countertransportJournal Of Hypertension, 1998
- A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1995
- Combined Treatment with Captopril, Hydrochlorothiazide and Pravastatin in Dyslipidemic Hypertensive PatientsBlood Pressure, 1995
- Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway productsAtherosclerosis, 1991
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987